A phase II open-label trial of avelumab plus axitinib in previously treated non-small-cell lung cancer or treatment-naïve, cisplatin-ineligible urothelial cancer
| Autor: | Galffy, G., Lugowska, I., Poddubskaya, E.V., Cho, B.C., Ahn, M.-J., Han, J.-Y., Su, W.-C., Hauke, R.J., Dyar, S.H., Lee, D.H., Serwatowski, P., Estelles, D.L., Holden, V.R., Kim, Y.J., Vladimirov, V., Horvath, Z., Ghose, A., Goldman, A., di Pietro, A., Wang, J., Murphy, D.A., Alhadab, A., Laskov, M. |
|---|---|
| Zdroj: | In ESMO Open June 2023 8(3) |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|